Lenalidomide Capsule Market

Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS). For MM it is used after at least one other treatment and generally together with dexamethasone.
Lenalidomide Capsule Market contains market size and forecasts of Lenalidomide Capsule in global, including the following market information:

• Global Lenalidomide Capsule Market Revenue, 2018-2023, 2023-2030, ($ millions)
• Global Lenalidomide Capsule Market Sales, 2018-2023, 2023-2030, (K Units)
• Global top five Lenalidomide Capsule companies in 2022 (%)

The global Lenalidomide Capsule market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
5 mg Capsules Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Lenalidomide Capsule include Celgene, SL Pharma, Qilu Pharma, Hansoh Pharma, CTTQ, Changzhou Pharma and Yangzijiang, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Lenalidomide Capsule manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Lenalidomide Capsule Market, by Type, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Lenalidomide Capsule Market Segment Percentages, by Type, 2022 (%)

• 5 mg Capsules
• 10 mg Capsules
• 15 mg Capsules
• 25 mg Capsules

Global Lenalidomide Capsule Market, by Application, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Lenalidomide Capsule Market Segment Percentages, by Application, 2022 (%)

• Multiple myeloma (MM)
• Myelodysplastic syndromes (MDS)

Global Lenalidomide Capsule Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Lenalidomide Capsule Market Segment Percentages, By Region and Country, 2022 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:

• Key companies Lenalidomide Capsule revenues in global market, 2018-2023 (Estimated), ($ millions)
• Key companies Lenalidomide Capsule revenues share in global market, 2022 (%)
• Key companies Lenalidomide Capsule sales in global market, 2018-2023 (Estimated), (K Units)
• Key companies Lenalidomide Capsule sales share in global market, 2022 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Celgene
• SL Pharma
• Qilu Pharma
• Hansoh Pharma
• CTTQ
• Changzhou Pharma
• Yangzijiang

To know more about market statistics, Download a FREE Sample copy